Catalyst brief · Phase 3 readout · 26 days
Ralinepag: Ralinepag in PAH
United Therapeutics · $UTHR · built 19 Nov 2026 from 15 sourced facts · open on the radar
Analyst desk
Five AI analysts read the facts below. Each sentence shows the facts it rests on.
Trial design
- The trial's open-label design and single study arm may impact the convincingness of the results, as there is no blinding or comparison group to measure against. F4 F6
- The main goal of measuring treatment-emergent adverse events over up to 6 years focuses on safety and tolerability, which is an important aspect of the trial. F3 F5
- The large planned enrollment of 1,000 patients could provide a more robust understanding of the treatment's effects, but the lack of randomization and blinding may still affect the results' reliability. F2 F4
Base rates
- Historically, 62.1% of Phase 3 programmes in cardiovascular and metabolic moved on to a regulatory filing, which is an industry average and not a forecast for this trial. F11
- UTHR has a record of delaying trials, with 40% of its active Phase 2 and 3 trials having their dates moved back by more than 6 months. F12
- Past result-day moves are not provided, but the company's cash position and operating cash flow may be relevant to consider. F13 F14
The case for
The case against
- The trial's open-label design and single study arm may impact the convincingness of the results, which could lead to a failed trial or delayed reporting of results. F4 F6
- UTHR has a record of delaying trials, with 40% of its active Phase 2 and 3 trials having their dates moved back by more than 6 months, which increases the likelihood of this trial reporting late. F12
- The large planned enrollment of 1,000 patients and long measurement period of up to 6 years may pose challenges to the trial's timely completion, potentially leading to delays or a failed trial. F2 F5
- The lack of randomization and blinding in the trial design may affect the results' reliability, which could contribute to a failed trial or delayed reporting of results. F2 F4
Open questions
- Will the open-label design and lack of a comparison group significantly impact the convincingness of the trial results?
- Can the large planned enrollment of 1,000 patients offset the potential reliability issues due to the trial design?
- Will UTHR's history of delaying trials affect the timing of the Ralinepag trial readout?
7 AI sentences were removed by the fact check.
The facts
The trial
- F1Ralinepag is a Phase 3 trial of Ralinepag in PAH, sponsored by United Therapeutics (UTHR). source ↗
- F2The trial plans to enrol 1,000 patients. source ↗
What counts as success
- F3Main goal as written in the registry: Number of subjects with treatment-emergent adverse events [Safety and Tolerability]. source ↗
- F4Blinding: open label (no blinding). source ↗
- F5The main goal is measured over: Up to 6 years. source ↗
- F6Number of study arms: 1. source ↗
When
- F8The registry gives the primary completion date as Dec 2026 (an estimate), which is 26 days from 19 Nov 2026. source ↗
- F9That date is 27.0 months later than the date first registered for this trial (Sep 2024). source ↗
- F10The DataCutoff timing model estimates this trial finishes close to its registry date. source ↗
Recruitment
- F7The registry lists 190 sites. source ↗
Base rates
- F11Historically 62.1% of Phase 3 programmes in cardiovascular and metabolic (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
- F1240% of UTHR's active Phase 2 and 3 trials have moved their date back by more than 6 months. source ↗
Money, insiders and FDA
How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.